Nurix Therapeutics: Funding, Investors & Team (Oct 2026)
Nurix Therapeutics is a biopharmaceutical organization zeroed in on the revelation, improvement, and commercialization of little particle treatments intended to regulate cell protein levels as an original therapy approach for malignant growth and other testing sicknesses. Utilizing Nurix's broad mastery in E3 ligases along with its restrictive DNA-encoded libraries, Nurix has constructed DELigase, a coordinated revelation stage to recognize and propel novel medication up-and-comers focusing on E3 ligases, a wide class of chemicals that can tweak proteins inside the cell. Nurix's medication revelation approach is to one or the other tackle or restrain the regular capability of E3 ligases inside the ubiquitin proteasome framework to specifically diminish or increment cell protein levels. Nurix's entirely claimed pipeline incorporates designated protein degraders of Bruton's tyrosine kinase, a B-cell flagging protein, and inhibitors of Casitas B-heredity lymphoma proto-oncogene B, an E3 ligase that controls T cell enactment.
Nurix Therapeutics has raised $465M across 3 funding rounds on record, the most recent an undisclosed round of $250M announced in Oct 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nurix Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Nurix Therapeutics Funding Rounds
Nurix Therapeutics raised $40.0M in a Post-IPO Equity announced in Jul 2022.
1.8 years later, an undisclosed round of $175M was announced in Apr 2024.
1.5 years later, an undisclosed round of $250M was announced in Oct 2025.
Nurix Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Nurix Therapeutics Funding Compared to Other Biotechnology Startups
Nurix Therapeutics' latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nurix Therapeutics in Biotechnology and San Francisco
Companies Similar to Nurix Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Nurix Therapeutics Funding FAQs
What does Nurix Therapeutics do?
Nurix Therapeutics is a biopharmaceutical organization zeroed in on the revelation, improvement, and commercialization of little particle treatments intended to regulate cell protein levels as an original therapy approach for malignant growth and other testing sicknesses. Utilizing Nurix's broad mastery in E3 ligases along with its restrictive DNA-encoded libraries, Nurix has constructed DELigase, a coordinated revelation stage to recognize and propel novel medication up-and-comers focusing on E3 ligases, a wide class of chemicals that can tweak proteins inside the cell. Nurix's medication revelation approach is to one or the other tackle or restrain the regular capability of E3 ligases inside the ubiquitin proteasome framework to specifically diminish or increment cell protein levels. Nurix's entirely claimed pipeline incorporates designated protein degraders of Bruton's tyrosine kinase, a B-cell flagging protein, and inhibitors of Casitas B-heredity lymphoma proto-oncogene B, an E3 ligase that controls T cell enactment.
How much funding has Nurix Therapeutics raised?
Nurix Therapeutics has raised $465M across 3 rounds on record. The most recent is an undisclosed round of $250M announced in Oct 2025.
When did Nurix Therapeutics last raise funding?
Nurix Therapeutics' most recent funding round on record is an undisclosed round of $250M, announced in Oct 2025.
Who founded Nurix Therapeutics?
FundedIQ lists Arthur Weiss (Founder), John Kuriyan (Founder) at Nurix Therapeutics.
Where is Nurix Therapeutics headquartered?
Nurix Therapeutics is based in San Francisco, California, United States.
How many employees does Nurix Therapeutics have?
Nurix Therapeutics is in the 251-500 employee band.
How does Nurix Therapeutics' funding compare to other Biotechnology startups?
Nurix Therapeutics' latest round of $250M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Nurix Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nurix Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.